Cargando…
Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
Patients with central serous chorioretinopathy (CSC) often complain of visual difficulties under low luminance conditions. In this study, we evaluated low luminance visual acuity (LLVA) after half-dose verteporfin photodynamic therapy (hdPDT) in eyes with CSC. The study included eight eyes of eight...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764769/ https://www.ncbi.nlm.nih.gov/pubmed/33316889 http://dx.doi.org/10.3390/jcm9123980 |
_version_ | 1783628335350284288 |
---|---|
author | Fujita, Kyoko Shinoda, Kei Imamura, Yutaka Matsumoto, Celso Soiti Oda, Koichi |
author_facet | Fujita, Kyoko Shinoda, Kei Imamura, Yutaka Matsumoto, Celso Soiti Oda, Koichi |
author_sort | Fujita, Kyoko |
collection | PubMed |
description | Patients with central serous chorioretinopathy (CSC) often complain of visual difficulties under low luminance conditions. In this study, we evaluated low luminance visual acuity (LLVA) after half-dose verteporfin photodynamic therapy (hdPDT) in eyes with CSC. The study included eight eyes of eight patients with chronic CSC that underwent hdPDT. The best-corrected visual acuity, LLVA and optical coherence tomography (OCT) findings were evaluated at baseline, and at 1, 3, 6, 9, and 12 months after hdPDT. LLVA was measured at six levels of background luminance. Serous retinal detachment was completely resolved in all eyes. Although the mean LLVA at 1 month did not improve significantly compared to baseline at all luminance levels, significant improvements were observed at 3, 6, 9, and 12 months (p < 0.05). In OCT images, although the ellipsoid zone was not detectable in all eyes before hdPDT, it was observed in 2 eyes at 1 month, in 7 eyes at 3 months, and in all eyes from 6 months. The LLVA and the ellipsoid zone improved similarly with postoperative time courses. In conclusion, hdPDT improves LLVA in eyes with chronic CSC. The recovery of the ellipsoid zone may play a part in improving LLVA after hdPDT. |
format | Online Article Text |
id | pubmed-7764769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77647692020-12-27 Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy Fujita, Kyoko Shinoda, Kei Imamura, Yutaka Matsumoto, Celso Soiti Oda, Koichi J Clin Med Article Patients with central serous chorioretinopathy (CSC) often complain of visual difficulties under low luminance conditions. In this study, we evaluated low luminance visual acuity (LLVA) after half-dose verteporfin photodynamic therapy (hdPDT) in eyes with CSC. The study included eight eyes of eight patients with chronic CSC that underwent hdPDT. The best-corrected visual acuity, LLVA and optical coherence tomography (OCT) findings were evaluated at baseline, and at 1, 3, 6, 9, and 12 months after hdPDT. LLVA was measured at six levels of background luminance. Serous retinal detachment was completely resolved in all eyes. Although the mean LLVA at 1 month did not improve significantly compared to baseline at all luminance levels, significant improvements were observed at 3, 6, 9, and 12 months (p < 0.05). In OCT images, although the ellipsoid zone was not detectable in all eyes before hdPDT, it was observed in 2 eyes at 1 month, in 7 eyes at 3 months, and in all eyes from 6 months. The LLVA and the ellipsoid zone improved similarly with postoperative time courses. In conclusion, hdPDT improves LLVA in eyes with chronic CSC. The recovery of the ellipsoid zone may play a part in improving LLVA after hdPDT. MDPI 2020-12-09 /pmc/articles/PMC7764769/ /pubmed/33316889 http://dx.doi.org/10.3390/jcm9123980 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fujita, Kyoko Shinoda, Kei Imamura, Yutaka Matsumoto, Celso Soiti Oda, Koichi Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy |
title | Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy |
title_full | Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy |
title_fullStr | Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy |
title_full_unstemmed | Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy |
title_short | Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy |
title_sort | improvement of low luminance visual acuity in patients with chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764769/ https://www.ncbi.nlm.nih.gov/pubmed/33316889 http://dx.doi.org/10.3390/jcm9123980 |
work_keys_str_mv | AT fujitakyoko improvementoflowluminancevisualacuityinpatientswithchroniccentralserouschorioretinopathyafterhalfdoseverteporfinphotodynamictherapy AT shinodakei improvementoflowluminancevisualacuityinpatientswithchroniccentralserouschorioretinopathyafterhalfdoseverteporfinphotodynamictherapy AT imamurayutaka improvementoflowluminancevisualacuityinpatientswithchroniccentralserouschorioretinopathyafterhalfdoseverteporfinphotodynamictherapy AT matsumotocelsosoiti improvementoflowluminancevisualacuityinpatientswithchroniccentralserouschorioretinopathyafterhalfdoseverteporfinphotodynamictherapy AT odakoichi improvementoflowluminancevisualacuityinpatientswithchroniccentralserouschorioretinopathyafterhalfdoseverteporfinphotodynamictherapy |